P13: Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin? (original) (raw)

HemaSphere

Abstract

anti-CD38 antibodies (15%). Median OS was 9.79 months (95% CI: 7.79, 12.22), median PFS was 3.42 months (95% CI: 2.79, 4.27), and median TTNT was 3.61 months (95% CI: 3.09, 4.57). The following factors were prognostic for worse outcomes for OS (Figure) and PFS: higher refractory status (p<0.001), being male (p=0.001), older age (p<0.001), shorter duration of prior lines (p<0.001), shorter TTP in prior line (p=0.025), and higher lactate dehydrogenase levels (p<0.002). Conclusions: Real-world outcomes (OS, PFS, and TTNT) were poor in tri-exposed patients with RRMM. The wide variety of treatment regimens used in clinical practice confirms the absence of a clear SOC for these patients. These real-world data from patients in Belgium are consistent with those from other countries, underscoring the high unmet medical need for new and effective treatments for patients with RRMM.

P. Rodriguez-Otero hasn't uploaded this paper.

Let P. know you want this paper to be uploaded.

Ask for this paper to be uploaded.